12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial
Open Access
Abstract
Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups. Results: The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 μg and 20 μg HBsAg. Conclusions: At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 μg HBsAg for non-responders was more satisfactory.Keywords
Funding Information
- National Science and Technology Major Project on Infectious Diseases (2018ZX10721202)
- Fundamental Research Funds for the Central Universities and Peking University Health Science Center (BMU20170607)
This publication has 39 references indexed in Scilit:
- Long-term efficacy of 10–12 years after being immunized with Chinese hamster ovary cell derived hepatitis B vaccine in Chinese Rural CommunitiesVaccine, 2012
- Effectiveness of a Chinese hamster ovary cell derived hepatitis B vaccine in Chinese Rural CommunitiesVaccine, 2011
- Seroprevalence and Risk Factors for Hepatitis B Infection in an Adult Population in Northeast ChinaInternational Journal of Medical Sciences, 2011
- Long-term protection against hepatitis B after newborn vaccination: 20-year follow-upInfection, 2010
- Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccinationVaccine, 2009
- Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness†Hepatology, 2005
- The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta‐analysisClinical Infectious Diseases, 2002
- The cellular basis for lack of antibody response to hepatitis B vaccine in humans.Journal of Experimental Medicine, 1991
- Summary of safety and efficacy data on a yeast-derived hepatitis B vaccineThe American Journal of Medicine, 1989
- Overview of clinical studies with hepatitis B vaccine made by recombinant DNAJournal of Infection, 1986